Month: January 2026

SHENZHEN, CHINA, Jan. 30, 2026 (GLOBE NEWSWIRE) — China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a...

Raymond James engaged as financial advisor Reduction in force implementedNEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives. The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company’s workforce, to reduce operating expenses while the company explores strategic alternatives. About IO Biotech IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf...

Prospective observational study reports improvements in pain-related outcomes, mental health measures, and quality of life among patients using physician-authorized medical cannabis in the Canadian Journal of Pain TORONTO, Jan. 30, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, today announced the publication of results from an investigator-led Medical Cannabis Real-World Evidence (MCRWE) study conducted through the MyMedi.ca platform. The study led by Dr. Hance Clarke, Director of Pain Services at University Health Network (UHN), and has been published in the peer-reviewed Canadian Journal of Pain. The prospective, observational study...

− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − HighlightsPhase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter. Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026. Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development. Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and commercial planning. Cash balance of A$49.2 million at 31 December 2025.MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) —...

TORONTO, Jan. 30, 2026 (GLOBE NEWSWIRE) — Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) today reported new results from its underground exploration program at the Young-Davidson mine. Underground exploration drilling from both the mid and lower mine extended higher-grade gold mineralization within multiple zones in the hanging wall of the Young-Davidson deposit. In addition, expansion drilling within the Young-Davidson syenite continues to extend gold mineralization beyond Mineral Reserves and Mineral Resources. South Syenite Zone: high-grade gold mineralization intersected within a syenite intrusion located in the hanging wall, 285 metres (“m”) south of the Northgate Shaft in an area that has seen limited historical drilling. (Figures 1 and 2). New highlights include1:16.36 g/t Au (6.65 g/t Au cut) over 17.90...